Abstract:Our institution has evaluated pulsed radiation therapy (PRT) as a novel and effective treatment for glioblastoma in pre-clinical models. Here we describe our PRT delivery technique and report the preliminary clinical outcomes of a prospective, single-arm clinical trial investigating PRT in the treatment of newly diagnosed glioblastoma. Eight patients received 60 Gy PRT utilizing volumetric modulated arc radiation therapy (VMAT) with concurrent 75 mg/m2 temozolomide (TMZ), followed by maintenance 150-200 mg/m2 TMZ. An open-face, thermoplastic mask was used for immobilization during PRT. Each daily 2-Gy fraction comprised ten 0.2-Gy pulses; each pulse was delivered with the same arc separated by 3-minute intervals. The initial planning target volume (PTV) (FLAIR+2 cm) received 46 Gy; the boost PTV (T1+2.5 cm) received 14 Gy. Due to prolonged treatment time, we performed cone beam CT acquired prior to the first and sixth pulse. Brain MRI and neurocognitive, quality of life, and toxicity assessments were performed at baseline and at regular intervals. Toxicities were graded per CTCAEv4. Mean age was 61 yrs (50-70 yrs). A total of 4/2/2 patients underwent subtotal resection/near total resection/gross total resection, and 2 patients had a hypermethylated MGMT promotor. The mean ± SEM table adjustment in the x/y/z direction to correct for daily set-up error and intra-treatment movement was 1.2 ± 0.05 mm/2 ± 0.1 mm/1.4 ± 0.06 mm, and 0.4 ± 0.02 mm/0.7 ± 0.03 mm/0.6 ± 0.03 mm, respectively. At least 95% of the initial and boost PTV was covered with ≥95% of the prescription dose with each pulse, with a mean maximum dose of 0.22 ± 0.009 Gy. Mean arc length was 149 degrees (119-171 degrees) and took a mean 51 sec (47-62 sec) to deliver 0.2 Gy. With a mean follow-up of 11 mos (7-19 mos), all 7 patients who completed the minimum treatment including ≥6 mos maintenance TMZ are alive, with a mean progression-free survival of 7.9 mos. One patient, who received tumor "debulking," refused maintenance temozolomide, was lost to follow-up, and expired 10 mos after diagnosis. Maximal toxicities included grade1/2 alopecia (88%/13%), grade 1 scalp dermatitis (25%), grade 1 headache (34%), and grade 1/2 fatigue (25%/25%). Mean mini-mental status examination score at baseline and 6 mos following PRT was 27.4/30 and 29/30. This is the first reported use of PRT in the treatment of newly diagnosed glioblastoma. PRT is reproducible and well tolerated. VMAT allows appropriate PTV coverage with acceptable heterogeneity and pulse treatment duration. Preliminary progression-free survival rates are promising, and additional follow-up is needed to assess long-term clinical outcomes.

Particle Radiation Therapy in the Management of Malignant Glioma: Early Experience at the Shanghai Proton and Heavy Ion Center

Therapeutic Effects and Quality of Life in 37 Glioma Patients with Postoperative Intensity-Modulated Radiotherapy

[The preliminary report of a registration clinical trial of proton and heavy ion irradiation].

Carbon Ion Radiotherapy for Patients with Extracranial Chordoma or Chondrosarcoma - Initial Experience from Shanghai Proton and Heavy Ion Center

Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas

High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase

Tumor treating fields for newly diagnosed high‐grade glioma based on the criteria of 2021 WHO CNS5: A retrospective analysis of Chinese patients in a single center

Intensity‐Modulated Proton and Carbon‐Ion Radiation Therapy in the Management of Head and Neck Sarcomas

Pulsed Partial Brain Irradiation for Newly Diagnosed Glioblastoma

Dose Escalated Carbon Ion Radiotherapy for Localized Prostate Cancer in Shanghai Proton and Heavy Ion Center: Toxicity and Efficacy Outcomes At Two Years.

Radt-37. Proton Therapy Reirradiation For Recurrent Malignant Glioma: Prospective Analysis From The Proton Collaborative Group

Pulsed Partial-Brain Irradiation for Newly Diagnosed Glioblastoma: Feasibility and Preliminary Results of A Prospective Clinical Trial

Association of high‐dose radiotherapy with improved survival in patients with newly diagnosed low‐grade gliomas

Transitioning from conventional photon therapy to proton therapy for primary brain tumors

Long‐term outcomes following proton therapy for pediatric spinal low‐grade glioma

Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields

Long-term outcomes following proton therapy for non-metastatic central nervous system germinoma in children and adolescents

Post-operative Efficacy of Chemo-Radiotherapy and Prognosis Analysis on 112 Cases of High-Grade Gliomas

Carbon-ion radiotherapy in the treatment of radiation-induced second primary malignancies

Mixed Photon and Carbon-Ion Beam Radiotherapy in the Management of Non-Metastatic Nasopharyngeal Carcinoma

Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience